Inhibiting PCSK9 - biology beyond LDL control

Area of Science:

• Biochemistry
• Cardiovascular Medicine
• Pharmacology

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) is crucial for regulating LDL cholesterol by controlling LDL receptor levels.
• PCSK9 is expressed in multiple organs beyond the liver, including the pancreas, kidney, intestine, and central nervous system.
• Emerging evidence suggests PCSK9 has physiological roles independent of cholesterol metabolism.

Purpose of the Study:

• To review the physiological functions of PCSK9 beyond its role in LDL receptor regulation.
• To provide a scientific basis for monitoring potential effects of PCSK9 inhibitors in clinical practice.
• To assess the clinical relevance of PCSK9's non-cholesterol-related functions.

Main Methods:

• Literature review of in vitro and in vivo studies on PCSK9 function.
• Analysis of data from individuals with genetic PCSK9 deficiencies.
• Examination of clinical trial outcomes for PCSK9 inhibitors.

Main Results:

• Therapeutic PCSK9 inhibition effectively reduces LDL cholesterol and cardiovascular events.
• Studies indicate no significant adverse events associated with near-complete PCSK9 depletion.
• PCSK9's non-lipid-related physiological roles do not appear to cause clinically meaningful adverse effects with inhibition.

Conclusions:

• PCSK9 inhibition is a safe and effective strategy for cardiovascular risk reduction.
• The clinical implications of PCSK9's functions beyond lipid metabolism seem minimal.
• Further research can guide monitoring strategies for PCSK9 inhibitors in clinical use.